— Know what they know.
Not Investment Advice
Also trades as: FAGR.BR (BRU) · $vol 2M

ARSUF OTC

Fagron N.V.
1W: +0.0% 1M: +0.0% 3M: +3.7% YTD: +17.0% 1Y: +17.0% 3Y: +59.7% 5Y: +42.4%
$27.50
+0.00 (+0.00%)
 
OTC · Healthcare · Drug Manufacturers - Specialty & Generic · Tech Score Neutral · Power 57 · $2.0B mcap · 73M float · 0.0000% daily turnover · Short 100% of daily vol
Smart Money Score
No convergence signal
Key Statistics
Market Cap$2.0B
52W Range23.5-27.9
Volume2,500
Avg Volume6
Beta0.39
Dividend$0.46
Analyst Ratings
No analyst coverage
Company Info
CEORafael Padilla
Employees4,134
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2017-02-21
Websitefagron.com
Venecoweg 20A
Nazareth, VL 9810
BE
32 8 001 28 80
About Fagron N.V.

Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms